Efficacy outcomes demonstrated several clinically meaningful improvements in TD that were sustained throughout the 48-week treatment period in both the Ingrezza 40 mg and Ingrezza 80/40 mg groups. At all postbaseline visits from week 4 to week 48, the mean change from baseline in AIMS total score exceeded the minimally clinical important difference threshold, demonstrating rapid and continuous improvements with Ingrezza treatment. In participants who received 40 mg throughout the entire study, the percentage meeting the AIMS response threshold (≥50% total score improvement from baseline) generally increased over time, with 90% (18/20) of those completing 48 weeks reaching this threshold. The analysis also showed that participants who reduced their dose from 80 mg to 40 mg for tolerability reasons achieved similar therapeutic benefits.